KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBITDA (2020 - 2025)

Ginkgo Bioworks Holdings filings provide 6 years of EBITDA readings, the most recent being -$80.9 million for Q4 2025.

  • On a quarterly basis, EBITDA rose 26.19% to -$80.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$309.1 million, a 43.83% increase, with the full-year FY2025 number at -$309.1 million, up 43.83% from a year prior.
  • EBITDA hit -$80.9 million in Q4 2025 for Ginkgo Bioworks Holdings, down from -$80.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$26.7 million in Q3 2021 to a low of -$1.7 billion in Q4 2021.
  • Median EBITDA over the past 5 years was -$168.4 million (2022), compared with a mean of -$287.0 million.
  • Biggest five-year swings in EBITDA: tumbled 2914.48% in 2021 and later skyrocketed 90.04% in 2022.
  • Ginkgo Bioworks Holdings' EBITDA stood at -$1.7 billion in 2021, then skyrocketed by 90.04% to -$167.8 million in 2022, then fell by 23.55% to -$207.3 million in 2023, then skyrocketed by 47.13% to -$109.6 million in 2024, then grew by 26.19% to -$80.9 million in 2025.
  • The last three reported values for EBITDA were -$80.9 million (Q4 2025), -$80.4 million (Q3 2025), and -$57.8 million (Q2 2025) per Business Quant data.